Compare LYFT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYFT | ICUI |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 3.6B |
| IPO Year | 2019 | 1992 |
| Metric | LYFT | ICUI |
|---|---|---|
| Price | $19.70 | $139.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 5 |
| Target Price | $22.55 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 10.9M | 212.7K |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $6,273,827,000.00 | $2,320,363,000.00 |
| Revenue This Year | $14.34 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $54.54 | ★ N/A |
| Revenue Growth | ★ 14.90 | N/A |
| 52 Week Low | $9.66 | $107.00 |
| 52 Week High | $25.54 | $175.51 |
| Indicator | LYFT | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 40.50 |
| Support Level | $19.08 | $146.11 |
| Resistance Level | $19.78 | $149.00 |
| Average True Range (ATR) | 0.60 | 3.50 |
| MACD | -0.02 | -1.27 |
| Stochastic Oscillator | 49.77 | 8.25 |
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.